AB0111 Extracellular 14-3-3 ETA represents a novel rheumatology biomarker and drug target for personalized medicine

• Published in: Annals of the rheumatic diseases Vol. 71; no. Suppl 3; p. 644
• Main Authors: Marotta, A., Kilani, R., Ghahary, A., Maksymowych, W.P.
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and European League Against Rheumatism 01.06.2013; BMJ Publishing Group LTD
• Subjects: Precision medicine

Background 14-3-3η is a novel therapeutic target that stimulates specific cell lines (THP-1), activates disease-specific pathways (MAPK) and potentiates pathogenic factors (TNFα, IL-6). Clinically, 14-3-3η serum expression is higher in both erosive RA and PsA, correlates strongly with both synovial...